Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors. Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use https://www.novctrd.com/CtrdWeb/home.novfor complete trial results.

    Summary
    EudraCT number
    2012-000769-19
    Trial protocol
    ES   GB   IT   FR   NL   PL  
    Global end of trial date
    17 Sep 2014

    Results information
    Results version number
    v1(current)
    This version publication date
    07 Jul 2018
    First version publication date
    07 Jul 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CBEZ235Z2401
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01628913
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Novartis Pharma AG
    Sponsor organisation address
    CH-4002, Basel, Switzerland,
    Public contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
    Scientific contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    19 Aug 2014
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    17 Sep 2014
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To assess the treatment effect of BEZ235 relative to everolimus on progression free survival (PFS) in patients with advanced pNET who have not been previously treated with an mTOR inhibitor.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    26 Oct 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    France: 8
    Country: Number of subjects enrolled
    United Kingdom: 7
    Country: Number of subjects enrolled
    Italy: 5
    Country: Number of subjects enrolled
    Netherlands: 5
    Country: Number of subjects enrolled
    Russian Federation: 2
    Country: Number of subjects enrolled
    Spain: 24
    Country: Number of subjects enrolled
    United States: 11
    Worldwide total number of subjects
    62
    EEA total number of subjects
    49
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    45
    From 65 to 84 years
    17
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Patients were assigned to one of the following 2 treatment arms in a ratio of 1:1: BEZ235 (investigational arm) or everolimus (control arm)

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    BEZ235
    Arm description
    Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
    Arm type
    Experimental

    Investigational medicinal product name
    BEZ235
    Investigational medicinal product code
    BEZ235
    Other name
    Pharmaceutical forms
    Granules in sachet
    Routes of administration
    Oral use
    Dosage and administration details
    Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)

    Arm title
    Everolimus
    Arm description
    Patients received Everolimus 10 mg qd p.o. (by mouth, daily)
    Arm type
    Active comparator

    Investigational medicinal product name
    Everolimus
    Investigational medicinal product code
    RAD001
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Patients received Everolimus 10 mg qd p.o. (by mouth, daily)

    Number of subjects in period 1
    BEZ235 Everolimus
    Started
    31
    31
    Completed
    0
    0
    Not completed
    31
    31
         Adverse event, serious fatal
    1
    -
         Consent withdrawn by subject
    1
    -
         Physician decision
    1
    3
         study terminated by Sponsor
    4
    9
         Adverse event, non-fatal
    12
    5
         Disease Progression
    11
    14
         Protocol deviation
    1
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    BEZ235
    Reporting group description
    Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)

    Reporting group title
    Everolimus
    Reporting group description
    Patients received Everolimus 10 mg qd p.o. (by mouth, daily)

    Reporting group values
    BEZ235 Everolimus Total
    Number of subjects
    31 31 62
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    25 20 45
        From 65-84 years
    6 11 17
        85 years and over
    0 0 0
    Age Continuous |
    Units: Years
        arithmetic mean (standard deviation)
    56.3 ( 12.43 ) 57.8 ( 11.85 ) -
    Gender, Male/Female
    Units: participants
        Female
    14 16 30
        Male
    17 15 32

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    BEZ235
    Reporting group description
    Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)

    Reporting group title
    Everolimus
    Reporting group description
    Patients received Everolimus 10 mg qd p.o. (by mouth, daily)

    Primary: Progression free survival (PFS)

    Close Top of page
    End point title
    Progression free survival (PFS) [1]
    End point description
    PFS is defined as the time from the date of randomization until the date of the first radiologically documented disease progression or death due to any cause. PFS is based on local investigator assessment. Patients will be followed up for the duration of the study and for an expected average of every 12 weeks after randomization. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of all target lesions, or unequivocal progression of non-target lesions, or the appearance of new lesions. In the data table, 99999.9 represents “not applicable” data and used as place holder to avoid system error because EudraCT system is not accepting "NA" for not available/not applicable data.
    End point type
    Primary
    End point timeframe
    up to approx. 18 months
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical Analyses have been specified as the trial was terminated based on an interim analysis.
    End point values
    BEZ235 Everolimus
    Number of subjects analysed
    31
    31
    Units: Months
        median (confidence interval 95%)
    8.2 (5.3 to 999.99)
    10.8 (8.1 to 999.99)
    No statistical analyses for this end point

    Secondary: Objective response rate

    Close Top of page
    End point title
    Objective response rate
    End point description
    Proportion of patients with a best overall response during the study of complete response (CR) or partial response (PR), based on the investigator assessment. 2. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for all target and non-target lesions, as well as new lesions as assessed by CT or MRI: Complete Response (CR), Disappearance of all target and non-target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of all target lesions; Overall Response (OR) = CR + PR.
    End point type
    Secondary
    End point timeframe
    up to approx. 18 months
    End point values
    BEZ235 Everolimus
    Number of subjects analysed
    0 [2]
    0 [3]
    Units: Patients
    Notes
    [2] - Trial was terminated based on an interim analysis.
    [3] - Trial was terminated based on an interim analysis.
    No statistical analyses for this end point

    Secondary: Overall survival (OS)

    Close Top of page
    End point title
    Overall survival (OS)
    End point description
    Time from randomization to the date of death due to any cause
    End point type
    Secondary
    End point timeframe
    up to approx. 30 months
    End point values
    BEZ235 Everolimus
    Number of subjects analysed
    0 [4]
    0 [5]
    Units: Participants
    Notes
    [4] - Trial was terminated based on an interim analysis.
    [5] - Trial was terminated based on an interim analysis.
    No statistical analyses for this end point

    Secondary: Time to treatment failure (TTF)

    Close Top of page
    End point title
    Time to treatment failure (TTF)
    End point description
    Time from randomization to the date of the first of the following events:death due to any cause or progressive disease, treatment discontinuation due to toxicity or treatment discontinuation due to patient preference
    End point type
    Secondary
    End point timeframe
    up to approx. 18 months
    End point values
    BEZ235 Everolimus
    Number of subjects analysed
    0 [6]
    0 [7]
    Units: Time
    Notes
    [6] - Trial was terminated based on an interim analysis.
    [7] - Trial was terminated based on an interim analysis.
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.
    Adverse event reporting additional description
    Consistent with EudraCT disclosure specifications, Novartis has reported under the Serious adverse events field “number of deaths resulting from adverse events” all those deaths, resulting from serious adverse events that are deemed to be causally related to treatment by the investigator.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    17.0
    Reporting groups
    Reporting group title
    Everolimus
    Reporting group description
    Patients received Everolimus 10 mg qd p.o. (by mouth, daily)

    Reporting group title
    BEZ235
    Reporting group description
    Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)

    Serious adverse events
    Everolimus BEZ235
    Total subjects affected by serious adverse events
         subjects affected / exposed
    9 / 31 (29.03%)
    11 / 31 (35.48%)
         number of deaths (all causes)
    0
    1
         number of deaths resulting from adverse events
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    B-cell lymphoma stage III
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    Hypertension
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Embolism
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Peripheral artery aneurysm
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General disorders and administration site conditions
    General physical health deterioration
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pain
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    1 / 31 (3.23%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Confusional state
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Femur fracture
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac failure congestive
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal wall haematoma
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ascites
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 31 (0.00%)
    3 / 31 (9.68%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Large intestinal obstruction
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Nephritis
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Endocrine disorders
    Adrenal insufficiency
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cushing's syndrome
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Escherichia sepsis
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Febrile infection
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Viral infection
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hypercalcaemia
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperglycaemia
         subjects affected / exposed
    0 / 31 (0.00%)
    1 / 31 (3.23%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    1 / 31 (3.23%)
    0 / 31 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Everolimus BEZ235
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    30 / 31 (96.77%)
    31 / 31 (100.00%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    2 / 31 (6.45%)
    2 / 31 (6.45%)
         occurrences all number
    2
    2
    General disorders and administration site conditions
    Face oedema
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    3
    0
    Asthenia
         subjects affected / exposed
    13 / 31 (41.94%)
    13 / 31 (41.94%)
         occurrences all number
    28
    24
    Non-cardiac chest pain
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Mucosal inflammation
         subjects affected / exposed
    3 / 31 (9.68%)
    1 / 31 (3.23%)
         occurrences all number
    3
    1
    Influenza like illness
         subjects affected / exposed
    2 / 31 (6.45%)
    3 / 31 (9.68%)
         occurrences all number
    2
    3
    Oedema peripheral
         subjects affected / exposed
    11 / 31 (35.48%)
    6 / 31 (19.35%)
         occurrences all number
    13
    7
    Fatigue
         subjects affected / exposed
    10 / 31 (32.26%)
    7 / 31 (22.58%)
         occurrences all number
    12
    11
    Pyrexia
         subjects affected / exposed
    4 / 31 (12.90%)
    9 / 31 (29.03%)
         occurrences all number
    6
    11
    Xerosis
         subjects affected / exposed
    3 / 31 (9.68%)
    0 / 31 (0.00%)
         occurrences all number
    4
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    8 / 31 (25.81%)
    3 / 31 (9.68%)
         occurrences all number
    12
    4
    Dyspnoea
         subjects affected / exposed
    5 / 31 (16.13%)
    1 / 31 (3.23%)
         occurrences all number
    8
    1
    Epistaxis
         subjects affected / exposed
    5 / 31 (16.13%)
    4 / 31 (12.90%)
         occurrences all number
    5
    4
    Nasal inflammation
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    3
    Pneumonitis
         subjects affected / exposed
    4 / 31 (12.90%)
    0 / 31 (0.00%)
         occurrences all number
    4
    0
    Productive cough
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    2 / 31 (6.45%)
    3 / 31 (9.68%)
         occurrences all number
    2
    3
    Insomnia
         subjects affected / exposed
    3 / 31 (9.68%)
    1 / 31 (3.23%)
         occurrences all number
    3
    1
    Investigations
    Aspartate aminotransferase increased
         subjects affected / exposed
    2 / 31 (6.45%)
    4 / 31 (12.90%)
         occurrences all number
    2
    7
    Alanine aminotransferase increased
         subjects affected / exposed
    3 / 31 (9.68%)
    5 / 31 (16.13%)
         occurrences all number
    3
    6
    Blood cholesterol increased
         subjects affected / exposed
    4 / 31 (12.90%)
    1 / 31 (3.23%)
         occurrences all number
    4
    1
    Blood creatinine increased
         subjects affected / exposed
    2 / 31 (6.45%)
    6 / 31 (19.35%)
         occurrences all number
    2
    8
    Cardiac murmur
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    0 / 31 (0.00%)
    3 / 31 (9.68%)
         occurrences all number
    0
    3
    Pancreatic enzymes decreased
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    2
    Weight decreased
         subjects affected / exposed
    6 / 31 (19.35%)
    4 / 31 (12.90%)
         occurrences all number
    6
    5
    Platelet count decreased
         subjects affected / exposed
    7 / 31 (22.58%)
    0 / 31 (0.00%)
         occurrences all number
    9
    0
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    1 / 31 (3.23%)
    2 / 31 (6.45%)
         occurrences all number
    1
    2
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Dysgeusia
         subjects affected / exposed
    3 / 31 (9.68%)
    5 / 31 (16.13%)
         occurrences all number
    3
    5
    Tremor
         subjects affected / exposed
    1 / 31 (3.23%)
    2 / 31 (6.45%)
         occurrences all number
    1
    2
    Lethargy
         subjects affected / exposed
    1 / 31 (3.23%)
    2 / 31 (6.45%)
         occurrences all number
    1
    3
    Headache
         subjects affected / exposed
    7 / 31 (22.58%)
    6 / 31 (19.35%)
         occurrences all number
    13
    6
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    11 / 31 (35.48%)
    8 / 31 (25.81%)
         occurrences all number
    14
    15
    Leukocytosis
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    2
    Neutropenia
         subjects affected / exposed
    2 / 31 (6.45%)
    2 / 31 (6.45%)
         occurrences all number
    8
    2
    Thrombocytopenia
         subjects affected / exposed
    4 / 31 (12.90%)
    2 / 31 (6.45%)
         occurrences all number
    5
    2
    Gastrointestinal disorders
    Abdominal distension
         subjects affected / exposed
    3 / 31 (9.68%)
    1 / 31 (3.23%)
         occurrences all number
    4
    1
    Cheilitis
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Abdominal pain upper
         subjects affected / exposed
    5 / 31 (16.13%)
    5 / 31 (16.13%)
         occurrences all number
    8
    8
    Abdominal pain
         subjects affected / exposed
    8 / 31 (25.81%)
    12 / 31 (38.71%)
         occurrences all number
    11
    16
    Constipation
         subjects affected / exposed
    5 / 31 (16.13%)
    4 / 31 (12.90%)
         occurrences all number
    8
    4
    Diarrhoea
         subjects affected / exposed
    17 / 31 (54.84%)
    28 / 31 (90.32%)
         occurrences all number
    36
    64
    Dry mouth
         subjects affected / exposed
    4 / 31 (12.90%)
    0 / 31 (0.00%)
         occurrences all number
    4
    0
    Dyspepsia
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    2
    Dysphagia
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    2
    Flatulence
         subjects affected / exposed
    2 / 31 (6.45%)
    4 / 31 (12.90%)
         occurrences all number
    2
    4
    Haemorrhoids
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    2
    Mouth ulceration
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    4
    0
    Nausea
         subjects affected / exposed
    10 / 31 (32.26%)
    17 / 31 (54.84%)
         occurrences all number
    15
    28
    Oesophagitis
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    2
    Proctitis
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    2
    Proctalgia
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    2
    Rectal haemorrhage
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    3
    Stomatitis
         subjects affected / exposed
    20 / 31 (64.52%)
    23 / 31 (74.19%)
         occurrences all number
    35
    34
    Vomiting
         subjects affected / exposed
    7 / 31 (22.58%)
    14 / 31 (45.16%)
         occurrences all number
    16
    20
    Toothache
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    1 / 31 (3.23%)
    2 / 31 (6.45%)
         occurrences all number
    1
    2
    Acne
         subjects affected / exposed
    2 / 31 (6.45%)
    1 / 31 (3.23%)
         occurrences all number
    2
    1
    Dry skin
         subjects affected / exposed
    8 / 31 (25.81%)
    0 / 31 (0.00%)
         occurrences all number
    10
    0
    Eczema
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    5
    0
    Erythema
         subjects affected / exposed
    4 / 31 (12.90%)
    2 / 31 (6.45%)
         occurrences all number
    5
    2
    Onychoclasis
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Pruritus
         subjects affected / exposed
    2 / 31 (6.45%)
    6 / 31 (19.35%)
         occurrences all number
    5
    7
    Rash
         subjects affected / exposed
    13 / 31 (41.94%)
    11 / 31 (35.48%)
         occurrences all number
    16
    17
    Skin exfoliation
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Rash maculo-papular
         subjects affected / exposed
    2 / 31 (6.45%)
    1 / 31 (3.23%)
         occurrences all number
    3
    1
    Rash pruritic
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    3
    Skin lesion
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    2
    0
    Renal and urinary disorders
    Renal failure
         subjects affected / exposed
    1 / 31 (3.23%)
    2 / 31 (6.45%)
         occurrences all number
    1
    2
    Proteinuria
         subjects affected / exposed
    0 / 31 (0.00%)
    2 / 31 (6.45%)
         occurrences all number
    0
    2
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    4 / 31 (12.90%)
    3 / 31 (9.68%)
         occurrences all number
    5
    3
    Back pain
         subjects affected / exposed
    2 / 31 (6.45%)
    4 / 31 (12.90%)
         occurrences all number
    2
    4
    Musculoskeletal pain
         subjects affected / exposed
    1 / 31 (3.23%)
    2 / 31 (6.45%)
         occurrences all number
    1
    2
    Myalgia
         subjects affected / exposed
    1 / 31 (3.23%)
    3 / 31 (9.68%)
         occurrences all number
    1
    3
    Pain in extremity
         subjects affected / exposed
    3 / 31 (9.68%)
    3 / 31 (9.68%)
         occurrences all number
    3
    5
    Pain in jaw
         subjects affected / exposed
    2 / 31 (6.45%)
    1 / 31 (3.23%)
         occurrences all number
    2
    1
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    5 / 31 (16.13%)
    2 / 31 (6.45%)
         occurrences all number
    5
    2
    Conjunctivitis
         subjects affected / exposed
    2 / 31 (6.45%)
    1 / 31 (3.23%)
         occurrences all number
    3
    1
    Oral herpes
         subjects affected / exposed
    2 / 31 (6.45%)
    0 / 31 (0.00%)
         occurrences all number
    3
    0
    Tooth infection
         subjects affected / exposed
    4 / 31 (12.90%)
    0 / 31 (0.00%)
         occurrences all number
    4
    0
    Upper respiratory tract infection
         subjects affected / exposed
    3 / 31 (9.68%)
    3 / 31 (9.68%)
         occurrences all number
    3
    3
    Urinary tract infection
         subjects affected / exposed
    0 / 31 (0.00%)
    3 / 31 (9.68%)
         occurrences all number
    0
    4
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    13 / 31 (41.94%)
    9 / 31 (29.03%)
         occurrences all number
    16
    11
    Hypercholesterolaemia
         subjects affected / exposed
    4 / 31 (12.90%)
    0 / 31 (0.00%)
         occurrences all number
    6
    0
    Hyperglycaemia
         subjects affected / exposed
    11 / 31 (35.48%)
    9 / 31 (29.03%)
         occurrences all number
    12
    10
    Hyponatraemia
         subjects affected / exposed
    1 / 31 (3.23%)
    2 / 31 (6.45%)
         occurrences all number
    1
    2
    Hypokalaemia
         subjects affected / exposed
    2 / 31 (6.45%)
    1 / 31 (3.23%)
         occurrences all number
    3
    1
    Hypertriglyceridaemia
         subjects affected / exposed
    5 / 31 (16.13%)
    0 / 31 (0.00%)
         occurrences all number
    5
    0
    Hypophosphataemia
         subjects affected / exposed
    2 / 31 (6.45%)
    1 / 31 (3.23%)
         occurrences all number
    2
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    12 Feb 2014
    Number of patients was revised to reflect the total number of patients enrolled at the time of the halt of enrollment, and updated the time point for the main (safety and efficacy) analysis to be performed. Following an unplanned, preliminary assessment of the first randomized patients further enrollment into the study was terminated on 20-Sep-2013 with a last patient randomized on 29-Oct-2013. They were followed per protocol for approximately 6 months after the last patient started the study treatment and that the new cut-off date for the final (safety and efficacy) analysis was performed approximately 6 months after the last patient had started study treatment. The statistical considerations section was updated as the initially planned efficacy criteria would not be met. Laboratory evaluation and cardiac assessments were updated to reflect that not all tests were collected post approximately 6 months after the last patient had started study treatment.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Trial terminated based on the results of a pre-planned interim analysis of the primary OM ( which demonstrated BEX235 not having improved PFS (progression free survival) vs everolimus). The secondary OM analyses were not conducted.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:02:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA